LLY

As part of the agreement, Hims said it won't compound GLP-1 medications like Zepbound in the future.

Hims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant's GLP-1s on its consumer platform.

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform.

Eli Lilly's post-Q3 earnings rally highlights its surging drug demand. Discover 4 healthcare ETFs offering LLY exposure.

Eli Lilly just crushed earnings and raised guidance, yet the most compelling part of its story has almost nothing to do with what already happened.

Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end of the trials Detailed Phase 3b TOGETHER-PsA data showed positive results across disease activity, patient-reported and metabolic outcomes at one year for Taltz and Zepbound vs. Taltz alone in adults with psoriatic arthritis and obesity INDIANAPOLIS, Nov. 5, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new clinical and real-world research in people with knee osteoarthritis pain and obesity and those with psoriatic arthritis and obesity at the American College of Rheumatology (ACR) Convergence 2026, taking place Nov. 6-11 in Orlando.

Eli Lilly is positioned as the primary beneficiary of AI-driven drug discovery, leveraging its scale and research infrastructure. LLY's integration of AI accelerates new molecule development, enabling rapid expansion of product lines and access to untapped markets. Despite a forward P/E of 40, I rate LLY a Buy for the next 2–3 years, anticipating investor euphoria and substantial earnings growth.

Eli Lilly and Company delivered 39% revenue growth, driven by 53% volume gains despite a 15% decline in realized prices; gross margin rose to 83.9%. Eli Lilly's Strong Buy rating reflects robust growth, high margins, and strong momentum, but earnings were impacted by $4.57/share in acquired R&D charges. Two-thirds of revenue comes from tirzepatide (Mounjaro/Zepbound), heightening concentration risk as patent expiration looms and pricing pressure intensifies.

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Eli Lilly and Company's LLY stock has risen 9.6% since it announced solid third-quarter results on Oct. 29. Lilly's third-quarter earnings and revenues comfortably exceeded estimates.